Gastrointestinal stromal tumor epidemiology and demographics: Difference between revisions
Akshun Kalia (talk | contribs) No edit summary |
Akshun Kalia (talk | contribs) No edit summary |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The incidence of gastrointestinal stromal tumors (GIST) is approximately 1.0-1.60 cases per 100,000 individuals worldwide. The prevalence of GIST is approximately 12.9 cases per 100,000 individuals worldwide. GIST commonly affects individuals older than 40 years of age with the median age of 60s. Males are more commonly affected by GIST than females. A study based on Surveillance, Epidemiology and End Results (SEER) registry data found that GIST usually affects individuals of the white race (72.2%). | The [[incidence]] of gastrointestinal stromal tumors (GIST) is approximately 1.0-1.60 cases per 100,000 individuals worldwide. The [[prevalence]] of GIST is approximately 12.9 cases per 100,000 individuals worldwide. GIST commonly affects individuals older than 40 years of age with the median age of 60s. Males are more commonly affected by GIST than females. A study based on [[The Surveillance, Epidemiology, and End Results Program|the Surveillance, Epidemiology, and End Results]] ([[The Surveillance, Epidemiology, and End Results Program|SEER]]) registry data found that GIST usually affects individuals of the white race (72.2%). | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
*The incidence of gastrointestinal stromal tumors (GIST) is approximately 1.0-1.60 cases per 100,000 individuals worldwide.<ref name="pmid8000994">{{cite journal |vauthors=Thomas RM, Sobin LH |title=Gastrointestinal cancer |journal=Cancer |volume=75 |issue=1 Suppl |pages=154–70 |year=1995 |pmid=8000994 |doi= |url=}}</ref> | *The [[incidence]] of gastrointestinal stromal tumors (GIST) is approximately 1.0-1.60 cases per 100,000 individuals worldwide.<ref name="pmid8000994">{{cite journal |vauthors=Thomas RM, Sobin LH |title=Gastrointestinal cancer |journal=Cancer |volume=75 |issue=1 Suppl |pages=154–70 |year=1995 |pmid=8000994 |doi= |url=}}</ref> | ||
*In United States, the annual incidence of GIST is approximately 1.54 cases per 100,000 individuals. Every year around 4000-5000 new cases of GIST are reported. | *In United States, the annual [[incidence]] of GIST is approximately 1.54 cases per 100,000 individuals. Every year around 4000-5000 new cases of GIST are reported. | ||
*The incidence of GIST in European nations is relatively similar to other countries. Population based studies have shown the following results: | *The [[incidence]] of GIST in European nations is relatively similar to other countries. Population based studies have shown the following results: | ||
**In Iceland, the annual incidence of GIST is approximately 1.2 cases per 100,000 individuals. | **In Iceland, the annual [[incidence]] of GIST is approximately 1.2 cases per 100,000 individuals. | ||
**In Sweden, the annual incidence of GIST is approximately 1.45 cases per 100,000 individuals. | **In Sweden, the annual [[incidence]] of GIST is approximately 1.45 cases per 100,000 individuals. | ||
**In Netherlands, the annual incidence of GIST is approximately 1.2 cases per 100,000 individuals. | **In Netherlands, the annual [[incidence]] of GIST is approximately 1.2 cases per 100,000 individuals. | ||
**In Spain, the annual incidence of GIST is approximately 1.09 cases per 100,000 individuals. | **In Spain, the annual [[incidence]] of GIST is approximately 1.09 cases per 100,000 individuals. | ||
*Recent studies have shown that the highest [[incidence]] of GIST have been reported in Hong Kong, Taiwan and northern Norway with an estimated 1.90-2.20 cases per 100,000 individuals. | |||
*Recent studies have shown that the highest incidence of GIST have been reported in Hong Kong, Taiwan and northern Norway with an estimated 1.90-2.20 cases per 100,000 individuals. | |||
===Prevalence=== | ===Prevalence=== | ||
*The prevalence of GIST is approximately 12.9 cases per 100,000 individuals worldwide.<ref name="pmid8000994">{{cite journal |vauthors=Thomas RM, Sobin LH |title=Gastrointestinal cancer |journal=Cancer |volume=75 |issue=1 Suppl |pages=154–70 |year=1995 |pmid=8000994 |doi= |url=}}</ref> | *The [[prevalence]] of GIST is approximately 12.9 cases per 100,000 individuals worldwide.<ref name="pmid8000994">{{cite journal |vauthors=Thomas RM, Sobin LH |title=Gastrointestinal cancer |journal=Cancer |volume=75 |issue=1 Suppl |pages=154–70 |year=1995 |pmid=8000994 |doi= |url=}}</ref> | ||
*With the use of new tyrosine kinase inhibitors such as imatinib, the prevalence of GIST is estimated to go upto 31.8 cases per 100,0000 individuals.<ref name="NilssonBümming2005">{{cite journal|last1=Nilsson|first1=Bengt|last2=Bümming|first2=Per|last3=Meis-Kindblom|first3=Jeanne M.|last4=Odén|first4=Anders|last5=Dortok|first5=Aydin|last6=Gustavsson|first6=Bengt|last7=Sablinska|first7=Katarzyna|last8=Kindblom|first8=Lars-Gunnar|title=Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era|journal=Cancer|volume=103|issue=4|year=2005|pages=821–829|issn=0008543X|doi=10.1002/cncr.20862}}</ref> | *With the use of new [[tyrosine kinase inhibitors]] such as [[imatinib]], the [[prevalence]] of GIST is estimated to go upto 31.8 cases per 100,0000 individuals.<ref name="NilssonBümming2005">{{cite journal|last1=Nilsson|first1=Bengt|last2=Bümming|first2=Per|last3=Meis-Kindblom|first3=Jeanne M.|last4=Odén|first4=Anders|last5=Dortok|first5=Aydin|last6=Gustavsson|first6=Bengt|last7=Sablinska|first7=Katarzyna|last8=Kindblom|first8=Lars-Gunnar|title=Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era|journal=Cancer|volume=103|issue=4|year=2005|pages=821–829|issn=0008543X|doi=10.1002/cncr.20862}}</ref> | ||
===Age=== | ===Age=== | ||
*Patients of all age groups may develop GIST. | *Patients of all age groups may develop GIST. | ||
*GIST commonly affects individuals older than 40 years of age with the median age of 60s. | *GIST commonly affects individuals older than 40 years of age with the [[median]] age of 60s. | ||
*GIST is extremely rare in patients younger than 30 years of age. | *GIST is extremely rare in patients younger than 30 years of age. | ||
===Race=== | ===Race=== | ||
*A study based on Surveillance, Epidemiology and End Results (SEER) registry data found that GIST usually affects individuals of the white race (72.2%). | *A study based on [[The Surveillance, Epidemiology, and End Results Program|the Surveillance, Epidemiology, and End Results]] ([[SEER]]) registry data found that GIST usually affects individuals of the white race (72.2%). | ||
*The SEER study also concluded that Blacks and Hispanics individuals are less likely to develop GIST.<ref name="pmid19651058">{{cite journal |vauthors=Cheung MC, Zhuge Y, Yang R, Koniaris LG |title=Disappearance of racial disparities in gastrointestinal stromal tumor outcomes |journal=J. Am. Coll. Surg. |volume=209 |issue=1 |pages=7–16 |year=2009 |pmid=19651058 |doi=10.1016/j.jamcollsurg.2009.03.018 |url=}}</ref> | *The SEER study also concluded that Blacks and Hispanics individuals are less likely to develop GIST.<ref name="pmid19651058">{{cite journal |vauthors=Cheung MC, Zhuge Y, Yang R, Koniaris LG |title=Disappearance of racial disparities in gastrointestinal stromal tumor outcomes |journal=J. Am. Coll. Surg. |volume=209 |issue=1 |pages=7–16 |year=2009 |pmid=19651058 |doi=10.1016/j.jamcollsurg.2009.03.018 |url=}}</ref> | ||
===Gender=== | ===Gender=== |
Revision as of 15:50, 15 December 2017
Gastrointestinal stromal tumor Microchapters |
Differentiating Gastrointestinal stromal tumor from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Gastrointestinal stromal tumor epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Gastrointestinal stromal tumor epidemiology and demographics |
FDA on Gastrointestinal stromal tumor epidemiology and demographics |
CDC on Gastrointestinal stromal tumor epidemiology and demographics |
Gastrointestinal stromal tumor epidemiology and demographics in the news |
Blogs on Gastrointestinal stromal tumor epidemiology and demographics |
Directions to Hospitals Treating Gastrointestinal stromal tumor |
Risk calculators and risk factors for Gastrointestinal stromal tumor epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]
Overview
The incidence of gastrointestinal stromal tumors (GIST) is approximately 1.0-1.60 cases per 100,000 individuals worldwide. The prevalence of GIST is approximately 12.9 cases per 100,000 individuals worldwide. GIST commonly affects individuals older than 40 years of age with the median age of 60s. Males are more commonly affected by GIST than females. A study based on the Surveillance, Epidemiology, and End Results (SEER) registry data found that GIST usually affects individuals of the white race (72.2%).
Epidemiology and Demographics
Incidence
- The incidence of gastrointestinal stromal tumors (GIST) is approximately 1.0-1.60 cases per 100,000 individuals worldwide.[1]
- In United States, the annual incidence of GIST is approximately 1.54 cases per 100,000 individuals. Every year around 4000-5000 new cases of GIST are reported.
- The incidence of GIST in European nations is relatively similar to other countries. Population based studies have shown the following results:
- In Iceland, the annual incidence of GIST is approximately 1.2 cases per 100,000 individuals.
- In Sweden, the annual incidence of GIST is approximately 1.45 cases per 100,000 individuals.
- In Netherlands, the annual incidence of GIST is approximately 1.2 cases per 100,000 individuals.
- In Spain, the annual incidence of GIST is approximately 1.09 cases per 100,000 individuals.
- Recent studies have shown that the highest incidence of GIST have been reported in Hong Kong, Taiwan and northern Norway with an estimated 1.90-2.20 cases per 100,000 individuals.
Prevalence
- The prevalence of GIST is approximately 12.9 cases per 100,000 individuals worldwide.[1]
- With the use of new tyrosine kinase inhibitors such as imatinib, the prevalence of GIST is estimated to go upto 31.8 cases per 100,0000 individuals.[2]
Age
- Patients of all age groups may develop GIST.
- GIST commonly affects individuals older than 40 years of age with the median age of 60s.
- GIST is extremely rare in patients younger than 30 years of age.
Race
- A study based on the Surveillance, Epidemiology, and End Results (SEER) registry data found that GIST usually affects individuals of the white race (72.2%).
- The SEER study also concluded that Blacks and Hispanics individuals are less likely to develop GIST.[3]
Gender
- Males are more commonly affected by GIST than females.
- The male to female ratio is approximately 1.1 to 1.
Region
- The majority of GIST cases were reported in Hong Kong, Shanghai (China), Taiwan; and northern Norway, with a an estimated 19-22 cases per million per year.
References
- ↑ 1.0 1.1 Thomas RM, Sobin LH (1995). "Gastrointestinal cancer". Cancer. 75 (1 Suppl): 154–70. PMID 8000994.
- ↑ Nilsson, Bengt; Bümming, Per; Meis-Kindblom, Jeanne M.; Odén, Anders; Dortok, Aydin; Gustavsson, Bengt; Sablinska, Katarzyna; Kindblom, Lars-Gunnar (2005). "Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era". Cancer. 103 (4): 821–829. doi:10.1002/cncr.20862. ISSN 0008-543X.
- ↑ Cheung MC, Zhuge Y, Yang R, Koniaris LG (2009). "Disappearance of racial disparities in gastrointestinal stromal tumor outcomes". J. Am. Coll. Surg. 209 (1): 7–16. doi:10.1016/j.jamcollsurg.2009.03.018. PMID 19651058.